Sugi Predict

Sugi Predict / Compounds / SCHEMBL2060264

SCHEMBL2060264

SCHEMBL2060264

CCOC(=O)c1cnc(N)c(C#CC2CC2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ CSF1R P07333 3/20 0.40
▸ LMNA P02545 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ MAOA P21397 1/20 0.38
▸ PTGER4 P35408 1/20 0.38
▸ P2RY12 Q9H244 2/20 0.38
▸ CHEK2 O96017 1/20 0.37
▸ ALOX15 P16050 1/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ TP53 P04637 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ PKM P14618 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2060261 0.78 GRM5 (0.48) CYP2C9CYP2C19KDM4EHSD17B10CSF1R
SCHEMBL4506539 0.75 PTGER4 (0.46) LMNACYP1A2CYP3A4MAOAPTGER4
SCHEMBL710842 0.74 CYP2C9 (0.53) CYP2C9CYP2C19HSD17B10LMNACYP1A2
SCHEMBL4510841 0.74 ALOX15 (0.41) LMNACYP1A2CYP3A4MAOAPTGER4
SCHEMBL28383608 0.73 CHEK2 (0.58) CYP2C9CYP2C19KDM4EHSD17B10LMNA
SCHEMBL16421721 0.73 CYP2C9 (0.51) CYP2C9CYP2C19LMNACYP1A2CYP3A4
SCHEMBL5320922 0.72 CYP2C9 (0.50) CYP2C9CYP2C19LMNACYP1A2CYP3A4
SCHEMBL451366 0.72 CYP2C19 (0.50) CYP2C9CYP2C19LMNACYP1A2CYP3A4
SCHEMBL19340032 0.72 CYP2C9 (0.50) CYP2C9CYP2C19KDM4ELMNACYP1A2
SCHEMBL1505679 0.72 CYP2C9 (0.50) CYP2C9CYP2C19LMNACYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9957259-B2 Selective HDAC1 and HDAC2 inhibitors REGENACY PHARMACEUTICALS, LLC (US) 2018-05-01 — — US disclosed
US-9957259-B2 Selective HDAC1 and HDAC2 inhibitors REGENACY PHARMACEUTICALS, LLC (US) 2018-05-01 — — US disclosed
US-20180030040-A1 SELECTIVE HDAC1 AND HDAC2 INHIBITORS ACETYLON PHARMACEUTICALS, INC. 2018-02-01 — — US disclosed
US-20180030040-A1 SELECTIVE HDAC1 AND HDAC2 INHIBITORS ACETYLON PHARMACEUTICALS, INC. 2018-02-01 — — US disclosed
US-9765066-B2 Selective HDAC1 and HDAC2 inhibitors REGENACY PHARMACEUTICALS, LLC (US) 2017-09-19 — — US disclosed
US-9765066-B2 Selective HDAC1 and HDAC2 inhibitors REGENACY PHARMACEUTICALS, LLC (US) 2017-09-19 — — US disclosed
US-20170044144-A1 SELECTIVE HDAC1 AND HDAC2 INHIBITORS REGENACY PHARMACEUTICALS, LLC 2017-02-16 — — US disclosed
US-20170044144-A1 SELECTIVE HDAC1 AND HDAC2 INHIBITORS REGENACY PHARMACEUTICALS, LLC 2017-02-16 — — US disclosed
US-9421212-B2 Selective HDAC1 and HDAC2 inhibitors ACETYLON PHARMACEUTICALS, INC. (US) 2016-08-23 — — US disclosed
US-9421212-B2 Selective HDAC1 and HDAC2 inhibitors ACETYLON PHARMACEUTICALS, INC. (US) 2016-08-23 — — US disclosed
US-20160067259-A1 SELECTIVE HDAC1 AND HDAC2 INHIBITORS ACETYLON PHARMACEUTICALS, INC. (US) 2016-03-10 — — US disclosed
US-9145412-B2 Selective HDAC1 and HDAC2 inhibitors ACETYLON PHARMACEUTICALS, INC. (US) 2015-09-29 — — US disclosed
US-9145412-B2 Selective HDAC1 and HDAC2 inhibitors ACETYLON PHARMACEUTICALS, INC. (US) 2015-09-29 — — US disclosed
US-20140128391-A1 SELECTIVE HDAC1 AND HDAC2 INHIBITORS REGENACY PHARMACEUTICALS, LLC 2014-05-08 — — US disclosed
US-20140128391-A1 SELECTIVE HDAC1 AND HDAC2 INHIBITORS REGENACY PHARMACEUTICALS, LLC 2014-05-08 — — US disclosed
EP-2081928-B1 Pyrrolo-pyridine kinase inhibitors BRISTOL MYERS SQUIBB CO (US) 2014-02-26 — — EP disclosed
US-8148361-B2 Kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-04-03 — — US disclosed
US-20100041636-A1 NOVEL KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-02-18 — — US disclosed
EP-2081928-A2 PYRROLO-PYRIDINE KINASE INHIBITORS Brystol-Myers Squibb Company (US) 2009-07-29 — — EP disclosed
WO-2008060907-A2 PYRROLO-PYRIDINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2008-05-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170044144-A1 SELECTIVE HDAC1 AND HDAC2 INHIBITORS HDAC1, HDAC2, HDAC11 CYP2C9 3544/4885CYP2C19 3803/4885KDM4E 1010/4885
US-20100041636-A1 NOVEL KINASE INHIBITORS IGF1R, FGFR1, FLT1 CYP2C9 3284/4885CYP2C19 2626/4885KDM4E 2582/4885
US-20180030040-A1 SELECTIVE HDAC1 AND HDAC2 INHIBITORS HDAC1, HDAC2, HDAC11 CYP2C9 3544/4885CYP2C19 3803/4885KDM4E 1010/4885
US-20160067259-A1 SELECTIVE HDAC1 AND HDAC2 INHIBITORS HDAC1, HDAC2, HDAC11 CYP2C9 3544/4885CYP2C19 3803/4885KDM4E 1010/4885
US-20140128391-A1 SELECTIVE HDAC1 AND HDAC2 INHIBITORS HDAC1, HDAC2, HDAC11 CYP2C9 3544/4885CYP2C19 3803/4885KDM4E 1010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.